HC Wainwright Raises Earnings Estimates for Journey Medical

Journey Medical Corporation (NASDAQ:DERM) – Stock analysts at HC Wainwright lifted their Q4 2026 earnings per share estimates for Journey Medical in a research report issued on Thursday, April 23rd. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of $0.22 for the quarter, up from their previous estimate of $0.17. HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Journey Medical’s current full-year earnings is $0.19 per share.

Journey Medical (NASDAQ:DERM) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.02. The company had revenue of $16.08 million during the quarter, compared to analyst estimates of $18.86 million. Journey Medical had a negative return on equity of 46.40% and a negative net margin of 18.48%.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Journey Medical in a research note on Monday. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Journey Medical currently has an average rating of “Hold” and an average target price of $13.00.

Journey Medical Trading Up 0.4%

DERM opened at $5.15 on Friday. The firm has a market cap of $140.75 million, a P/E ratio of -10.96 and a beta of 1.03. The stock has a 50-day moving average of $6.59 and a 200 day moving average of $7.48. Journey Medical has a 12 month low of $4.31 and a 12 month high of $9.56. The company has a current ratio of 1.79, a quick ratio of 1.53 and a debt-to-equity ratio of 0.79.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wasatch Advisors LP boosted its stake in Journey Medical by 62.1% during the first quarter. Wasatch Advisors LP now owns 2,133,370 shares of the company’s stock worth $10,006,000 after buying an additional 817,095 shares during the period. Invesco Ltd. purchased a new position in Journey Medical during the fourth quarter worth $127,000. XTX Topco Ltd purchased a new position in Journey Medical during the fourth quarter worth $126,000. Ikarian Capital LLC purchased a new position in Journey Medical during the fourth quarter worth $1,939,000. Finally, Occudo Quantitative Strategies LP boosted its stake in Journey Medical by 22.3% during the fourth quarter. Occudo Quantitative Strategies LP now owns 18,913 shares of the company’s stock worth $146,000 after buying an additional 3,443 shares during the period. 7.25% of the stock is owned by hedge funds and other institutional investors.

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.